<DOC>
	<DOCNO>NCT02089737</DOCNO>
	<brief_summary>The efficacy safety panitumumab ( Vectibix ) routine clinical setting study . Specifically , information collect follow event interest : skin disorder , interstitial lung disease , infusion reaction , electrolyte abnormality , cardiac disorder .</brief_summary>
	<brief_title>Panitumumab Intravenous Infusion 100 mg 400 mg Special Drug Use Surveillance `` Survey Unresectable , Advanced Recurrent Colorectal Cancer With Wild-type KRAS Gene '' ( All-patient Surveillance )</brief_title>
	<detailed_description>The efficacy safety panitumumab ( Vectibix ) routine clinical setting study . Participants surveillance patient unresectable , advanced recurrent colorectal cancer wild-type KRAS gene . The planned sample size 2,000 patient . The usual adult dosage 6 mg/kg panitumumab give intravenous drip infusion 60-minute period every 2 week . The dosage may also reduce need , depend patient 's condition .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Unresectable , advanced recurrent colorectal cancer wildtype KRAS gene Patients medical history severe hypersensitivity ingredient Vectibix</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>